

CITATION REPORT

List of articles citing

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience

DOI: 10.1097/rhu.ob013e3181a4f459

Journal of Clinical Rheumatology, 2009, 15, 161-4.

Source: <https://exaly.com/paper-pdf/47165633/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
100	Actual status of antiinterleukin-1 therapies in rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 246-51	5.3	42
99	Inflammasome and IL-1beta-mediated disorders. <i>Current Allergy and Asthma Reports</i> , 2010 , 10, 229-35	5.6	112
98	Current treatments for juvenile idiopathic arthritis. <i>Joint Bone Spine</i> , 2010 , 77, 511-6	2.9	27
97	A 21-year-old man with Still's disease with fever, rash, and pancytopenia. <i>Arthritis Care and Research</i> , 2010 , 62, 575-9	4.7	13
96	Actualit� th�rapeutiques des arthrites juv�niles idiopathiques. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010 , 77, A12-A17	0.1	1
95	The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 1743-52	5.4	30
94	The safety profile of biologic therapies for juvenile idiopathic arthritis. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 561-71	8.1	51
93	Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. <i>European Journal of Internal Medicine</i> , 2010 , 21, 157-63	3.9	102
92	SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. 2011 , 236-248		14
91	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. <i>Open Access Rheumatology: Research and Reviews</i> , 2011 , 3, 9-18 ^{2.4}		3
90	The emerging role of interleukin-1�n autoinflammatory diseases. <i>Current Allergy and Asthma Reports</i> , 2011 , 11, 361-8	5.6	28
89	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011 , 63, 465-82	4.7	531
88	The emerging role of interleukin-1�n autoinflammatory diseases. <i>Arthritis and Rheumatism</i> , 2011 , 63, 314-24		70
87	Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. <i>Arthritis and Rheumatism</i> , 2011 , 63, 545-55		326
86	Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. <i>Journal of Rheumatology</i> , 2011 , 38, 180-1	4.1	58
85	A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 747-54	2.4	378
84	Treatment options with biologics for juvenile idiopathic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2011 , 6, 305-323	1.5	1

83	Systemic arthritis in children: a review of clinical presentation and treatment. <i>International Journal of Inflammation</i> , 2012 , 2012, 271569	6.4	51
82	Review of biologics in children with rheumatic diseases. <i>International Journal of Clinical Rheumatology</i> , 2012 , 7, 81-93	1.5	
81	Macrophage activation syndrome. <i>Indian Journal of Rheumatology</i> , 2012 , 7, 27-35	0.5	4
80	Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 4135-42		59
79	Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist. <i>Pediatric Rheumatology</i> , 2012 , 10, 8	3.5	10
78	Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. <i>Genes and Immunity</i> , 2012 , 13, 289-98	4.4	261
77	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1001-10	4.7	114
76	Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. <i>Biologics in Therapy</i> , 2012 , 2, 1		9
75	2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic		177
74	2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Care and Research</i> , 2013 , 65, 1551-63	4.7	70
73	Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. <i>Particle and Fibre Toxicology</i> , 2013 , 10, 39	8.4	84
72	Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 975-89	4	5
71	What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?. <i>Arthritis Research and Therapy</i> , 2013 , 15, 213	5.7	21
70	Inflammasome and cytokine blocking strategies in autoinflammatory disorders. <i>Clinical Immunology</i> , 2013 , 147, 242-75	9	59
69	Update on biologics for treatment of juvenile idiopathic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 361-76	5.4	43
68	Long-term safety and efficacy of riloncept in patients with systemic juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2486-96		94
67	Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2013 , 65, 745-52	4.7	89
66	Evaluation of anakinra for the treatment of systemic juvenile idiopathic arthritis. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 181-188	1.1	

65	A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O480-8	9.5	26
64	Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2570-9	9.5	114
63	Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1405-13	9.5	105
62	Macrophage activation syndrome and cytokine-directed therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014 , 28, 277-92	5.3	105
61	Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. <i>Pediatric Rheumatology</i> , 2014 , 12, 28	3.5	22
60	Treatment of juvenile idiopathic arthritis: a revolution in care. <i>Pediatric Rheumatology</i> , 2014 , 12, 13	3.5	95
59	Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside. <i>Pediatric Rheumatology</i> , 2014 , 12, 16	3.5	8
58	Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature. <i>Case Reports in Medicine</i> , 2015 , 2015, 294041	0.7	19
57	The development and assessment of biological treatments for children. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 379-94	3.8	6
56	Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 575-88	5.1	12
55	Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab. <i>Journal of Rheumatology</i> , 2015 , 42, 712-22	4.1	62
54	Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. <i>RMD Open</i> , 2015 , 1, e000036	5.9	33
53	Macrophage Activation Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 927-41	3.1	87
52	Novel treatment options for juvenile idiopathic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 559-73	3.8	2
51	Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. <i>Annual Review of Medicine</i> , 2015 , 66, 145-59	17.4	212
50	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , 2015 , 14, 1-9	13.6	70
49	The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review. <i>Cardiology Research and Practice</i> , 2016 , 2016, 7840724	1.9	18
48	The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 210	5.7	30

47	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016 , 7, 467	5.6	33
46	Biologic therapies in systemic juvenile idiopathic arthritis. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 621-629		
45	Macrophage Activation Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2016 , 85-106	0.3	0
44	Management of Juvenile Idiopathic Arthritis: A Clinical Guide. <i>Paediatric Drugs</i> , 2016 , 18, 397-412	4.2	23
43	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. <i>Arthritis and Rheumatology</i> , 2016 , 68, 218-28	9.5	81
42	Updates in Pediatric Rheumatology. <i>Advances in Pediatrics</i> , 2016 , 63, 281-332	2.2	2
41	Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. <i>Rheumatology International</i> , 2016 , 36, 1421-9	3.6	32
40	Systemic Juvenile Idiopathic Arthritis. 2016 , 205-216.e6		13
39	Macrophage Activation Syndrome. 2016 , 642-649.e3		3
38	Macrophage activation syndrome in the era of biologic therapy. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 259-68	8.1	209
37	Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. <i>Endocrine Reviews</i> , 2016 , 37, 62-110	27.2	83
36	Macrophage Activation Syndrome. <i>Indian Journal of Pediatrics</i> , 2016 , 83, 248-53	3	25
35	Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. <i>Pediatric Rheumatology</i> , 2017 , 15, 5	3.5	92
34	New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets. <i>Current Cardiology Reports</i> , 2017 , 19, 60	4.2	19
33	Biologics in juvenile idiopathic arthritis: a narrative review. <i>European Journal of Pediatrics</i> , 2017 , 176, 1147-1153	4.1	27
32	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. <i>Journal of Pediatrics</i> , 2017 , 189, 31-39	3.6	1
31	How I treat juvenile idiopathic arthritis: A state of the art review. <i>Autoimmunity Reviews</i> , 2017 , 16, 1008-1015	19.6	22
30	Juvenile Idiopathic Arthritis. 2017 , 167-187		5

29	Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. <i>Clinical Rheumatology</i> , 2018 , 37, 3329-3335	3.9	63
28	Evidence-based clinical practice guideline for adult Still's disease. <i>Modern Rheumatology</i> , 2018 , 28, 736-757	5.3	21
27	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). <i>Clinical Trials</i> , 2018 , 15, 268-277	2.2	13
26	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2018 , 70, 409-419	4.7	72
25	The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative. <i>Journal Francais D'Ophtalmologie</i> , 2018 , 41, 759-766	0.8	8
24	Macrophage Activation Syndrome. 2018 , 151-182		4
23	The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1633-1643	4.4	27
22	Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery. <i>HSS Journal</i> , 2018 , 14, 214-221	2	4
21	Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. 2019 , 587-616		3
20	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. <i>Arthritis Research and Therapy</i> , 2019 , 21, 275	5.7	10
19	Systemic Juvenile Idiopathic Arthritis. 2019 , 169-191		
18	Macrophage Activation Syndrome (MAS). 2019 , 193-201		
17	Macrophage Activation Syndrome in Childhood Inflammatory Disorders: Diagnosis, Genetics, Pathophysiology, and Treatment. <i>Current Treatment Options in Rheumatology</i> , 2020 , 6, 245-259	1.3	
16	Non-viral Gene Delivery of Interleukin-1 Receptor Antagonist Using Collagen-Hydroxyapatite Scaffold Protects Rat BM-MSCs From IL-1 β Mediated Inhibition of Osteogenesis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020 , 8, 582012	5.8	5
15	The off-label use of anakinra in pediatric systemic autoinflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20959575	3.8	2
14	Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , 2021 , 9, 77-86	1.1	0
13	Intravenous administration of anakinra in children with macrophage activation syndrome. <i>Pediatric Rheumatology</i> , 2021 , 19, 98	3.5	3
12	Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis. 2019 , 349-379		1

11	MACROPHAGE ACTIVATION SYNDROME. 2011 , 674-681		4
10	Treatment advances in systemic juvenile idiopathic arthritis. <i>F1000prime Reports</i> , 2014 , 6, 21		26
9	Clinical benefits of intra-articular anakinra for arthrofibrosis. <i>Orthopedics</i> , 2010 , 33, 877	1.5	25
8	Treatment of Inflammasome-Related Disorders. 2011 , 209-220		
7	Autoimmune Skin Disorders (Collagen Vascular). 2016 , 119-129		
6	Biologic Response Modifiers in Pediatric Rheumatology. 2017 , 77-87		
5	Macrophage Activation Syndrome. 2017 , 275-292		
4	A Review on Macrophage Activation Syndrome. <i>Journal of Pure and Applied Microbiology</i> , 2019 , 13, 183-194		
3	Systemic-Onset Juvenile Idiopathic Arthritis. <i>Rare Diseases of the Immune System</i> , 2020 , 65-91	0.2	
2	Role of Distinct Macrophage Populations in the Development of Heart Failure in Macrophage Activation Syndrome.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
1	The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022 , 60, 280-298	0.9	2